Does evidence exist to include dietary therapy in the treatment of Crohns disease?

Expert Review of Gastroenterology and Hepatology

Volumn 4, Issue 2, 2010, Pages 191-215

  Brown, Amy C ^a   Roy, Minakshi ^b  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF HAWAII   (United States)

Author keywords

Crohns disease; Diet; Elimination; Gluten; Lactose

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID; MERCAPTOPURINE; OMEGA 3 FATTY ACID; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE;

CASEIN FREE DIET; CELIAC DISEASE; CROHN DISEASE; DIET; DIET RESTRICTION; DIET THERAPY; ELEMENTAL DIET; ENTERIC FEEDING; FOOD ALLERGY; GLUTEN FREE DIET; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; LACTASE DEFICIENCY; LACTOSE INTAKE; LACTOSE INTOLERANCE; MICROPARTICLE FREE DIET; NUTRITIONAL INTOLERANCE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREVALENCE; RELAPSE; REVIEW; SACCHAROMYCES CEREVISIAE; SPECIFIC CARBOHYDRATE DIET; TREATMENT OUTCOME; ULCERATIVE COLITIS; VITAMIN SUPPLEMENTATION; YEAST FREE DIET;

CROHN DISEASE; DIET THERAPY; DIET, GLUTEN-FREE; DIETARY CARBOHYDRATES; ENTERAL NUTRITION; FOOD HYPERSENSITIVITY; HUMANS;

EID: 77950477069     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.10.11     Document Type: Review

References (165)

1. Mayberry JF, Rhodes J. Epidemiological aspects of Crohn's disease: a review of the literature. Gut 25(8), 886-899 (1984). (Pubitemid 14053539)
2. Ruemmele FM, Roy CC, Levy E, Seidman EG. Nutrition as primary therapy in pediatric Crohn's disease: fact or fantasy? J. Pediatr. 136(3), 285-291 (2000). (Pubitemid 30470948)
3. Sleisenger MH, Terdiman JP, Conrad PG. Genetic testing in hereditary colorectal cancer: indications and procedures. Am. J. Gastroenterol. 94(9), 2344-2356 (1999). (Pubitemid 29420655)
4. Gasche C, Bakos S, Dejaco C, Tillinger W, Zakeri S, Reinisch W. IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease. J. Clin. Immunol. 20(5), 362-370 (2000).
5. Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol. 19(Suppl. A), 5-36 (2005).
6. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 369(9573), 1627-1640 (2007). (Pubitemid 46722636)
7. Appleyard CB, Hernández G, Rios-Bedoya CF. Basic epidemiology of inflammatory bowel disease in Puerto Rico. Inflamm. Bowel Dis. 10(2), 106-111 (2004). (Pubitemid 38332169)
8. Gupta N, Bostrom AG, Kirschner BS et al. Gender differences in presentation and course of disease in pediatric patients with Crohn's disease. Pediatrics 120(6), e1418-e1425 (2007). (Pubitemid 350223660)
9. Seksik P, Nion-Larmurier I, Sokol H, Beaugerie L, Cosnes J. Effects of light smoking consumption on the clinical course of Crohn's disease. Inflamm. Bowel Dis. 15(5), 734-741 (2009).
10. García-Vega E, Fernandez-Rodriguez C. A stress management programme for Crohn's disease. Behav. Res. Ther. 42(4), 367-383 (2004). (Pubitemid 38283819)
11. Ben-Horin S, Avidan B, Yanai H, Lang A, Chowers Y, Bar-Meir S. Familial clustering of Crohn's disease in Israel: prevalence and association with disease severity. Inflamm. Bowel Dis. 15(2), 171-175 (2009).
12. Kaplan GG, Jackson T, Sands BE, Frisch M, Andersson RE, Korzenic J. The risk of developing Crohn's disease after an appendectomy: a meta-analysis. Am. J. Gastroenterol. 103(11), 2925-2931 (2008).
13. Bjarnason I, Peters TJ. Intestinal permeability, non-steroidal anti-inflammatory drug enteropathy and inflammatory bowel disease: an overview. Gut 30, 22-28 (1989). (Pubitemid 20002479)
14. Ekbom A, Montgomery SM. Environmental risk factors (excluding tobacco and microorganisms): critical analysis of old and new hypotheses. Best Pract. Res. Clin. Gastroenterol. 18(3), 497-508 (2004). (Pubitemid 38667462)
15. Prantera C, Scribano ML. Antibiotics and probiotics in inflammatory bowel disease: why, when, and how. Curr. Opin. Gastroenterol. 25(4), 329-333 (2009).
16. Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J. Gastroenterol. 12(30), 4807-4812 (2006). (Pubitemid 44323204)
17. Lochs H, Dejong C, Hammarqvist F et al. ESPEN guidelines on enteral nutrition: gastroenterology. Clin. Nutr. 25, 260-274 (2006). (Pubitemid 43811680)
18. Yamamoto T, Nakahigashi M, Saniabadi AR. Review article: diet and inflammatory bowel disease - epidemiology and treatment. Aliment Pharmacol. Ther. 30(2), 99-112 (2009).
19. de Jong NS, Leach ST, Day AS. Polymeric formula has direct anti-inflammatory effects on enterocytes in an in vitro model of intestinal inflammation. Dig. Dis. Sci. 52(9), 2029-2036 (2007).
20. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 3, CD000542 (2007). (Pubitemid 351835440)
21. Dupont B, Dupont C, Justum AM, Piquet MA, Reimund JM. Enteral nutrition in adult Crohn's disease: present status and perspectives. Mol. Nutr. Food Res. 52(8), 875-884 (2008).
22. Akobeng AK, Richmond K, Miller V et al. Effect of exclusive enteral nutritional treatment on plasma antioxidant concentrations in childhood Crohn's disease. Clin. Nutr. 26(1), 51-56 (2007). (Pubitemid 46179126)
23. Yamamoto T, Nakahigashi M, Umegae S et al. Impact of long-term enteral nutrition on clinical and endoscopic recurrence after resection for Crohn's disease: a prospective, non-randomized, parallel, controlled study. Aliment. Pharmacol. Ther. 25(1), 67-72 (2007). (Pubitemid 44902865)
24. Takagi S, Utsunomiya K, Kuriyama S et al. Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn's disease: a randomized-controlled trial. Aliment. Pharmacol. Ther. 24(9), 1333-1340 (2006). (Pubitemid 44571563)
25. Johnson T, Macdonald S, Hill SM et al. Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial. Gut 55(3), 356-361 (2006). (Pubitemid 43268273)
26. Eivindson M, Grønbaek H, Nielsen JN et al. Insulin-like growth factors (IGFs) and IGF binding proteins in active Crohn's disease treated with omega-3 or omega-6 fatty acids and corticosteroids. Scand. J. Gastroenterol. 40(10), 1214-1221 (2005). (Pubitemid 41510681)
27. Matsumoto T, Iida M, Kohgo Y et al. Therapeutic efficacy of infliximab on active Crohn's disease under nutritional therapy. Scand. J. Gastroenterol. 40(12), 1423-1430 (2005). (Pubitemid 43028203)
28. Ludvigsson JF, Krantz M, Bodin L et al. Elemental versus polymeric enteral nutrition in paediatric Crohn's disease: a multicentre randomized controlled trial. Acta Paediatr. 93(3), 327-335 (2004). (Pubitemid 38316554)
29. Bamba T, Shimoyama T, Sasaki M et al. Dietary fat attenuates the benefits of an elemental diet in active Crohn's disease: a randomized, controlled trial. Eur. J. Gastroenterol. Hepatol. 15(2), 151-157 (2003). (Pubitemid 36269779)
30. Gassull MA, Fernández-Bañares F, Cabré E et al. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomised multicentre European trial. Gut 51(2), 164-168 (2002). (Pubitemid 34791440)
31. Sakurai T, Matsui T, Yao T et al. Short-term efficacy of enteral nutrition in the treatment of active Crohn's disease: a randomized, controlled trial comparing nutrient formulas. JPEN J. Parenter. Enteral. Nutr. 26(2), 98-103 (2002). (Pubitemid 34163552)
32. Verma S, Holdsworth CD, Giaffer MH. Does adjuvant nutritional support diminish steroid dependency in Crohn disease? Scand. J. Gastroenterol. 36(4), 383-388 (2001). (Pubitemid 32250734)
33. Verma S, Kirkwood B, Brown S et al. Oral nutritional supplementation is effective in the maintenance of remission in Crohn's disease. Dig. Liver Dis. 32(9), 769-774 (2000). (Pubitemid 32098074)
34. Fell JM, Paintin M, Arnaud-Battandier F et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment. Pharmacol. Ther. 14(3), 281-289 (2000). (Pubitemid 30145315)
35. Verma S, Brown S, Kirkwood B et al. Polymeric versus elemental diet as primary treatment in active Crohn's disease: a randomized, double-blind trial. Am. J. Gastroenterol. 95(3), 735-739 (2000). (Pubitemid 30123912)
36. Khoshoo V, Reifen R, Neuman MG et al. Effect of low- and high-fat, peptide-based diets on body composition and disease activity in adolescents with active Crohn's disease. JPEN J. Parenter. Enteral. Nutr. 20(6), 401-405 (1996). (Pubitemid 26399215)
37. Fukuda Y, Kosaka T, Okui M et al. Efficacy of nutritional therapy for active Crohn's disease. J. Gastroenterol. 30(Suppl. 8), 83-87 (1995).
38. Breese EJ, Michie CA, Nicholls SW et al. The effect of treatment on lymphokine-secreting cells in the intestinal mucosa of children with Crohn's disease. Aliment. Pharmacol. Ther. 9(5), 547-552 (1995).
39. Israel DM, Hassall E. Prolonged use of gastrostomy for enteral hyperalimentation in children with Crohn's disease. Am. J. Gastroenterol. 90(7), 1084-1088 (1995).
40. Royall D, Greenberg GR, Allard JP et al. Total enteral nutrition support improves body composition of patients with active Crohn's disease. JPEN J. Parenter. Enteral. Nutr. 19(2), 95-99 (1995).
41. Mansfield JC, Giaffer MH, Holdsworth CD. Controlled trial of oligopeptide versus amino acid diet in treatment of active Crohn's disease. Gut 36(1), 60-66 (1995).
42. Ruuska T, Savilahti E, Mäki M et al. Exclusive whole protein enteral diet versus prednisolone in the treatment of acute Crohn's disease in children. J. Pediatr. Gastroenterol. Nutr. 19(2), 175-180 (1994). (Pubitemid 24299626)
43. Royall D, Jeejeebhoy KN, Baker JP et al. Comparison of amino acid V peptide based enteral diets in active Crohn's disease: clinical and nutritional outcome. Gut 35(6), 783-787 (1994). (Pubitemid 24193222)
44. González-Huix F, de León R, Fernández-Bañares F et al. Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial. Gut 34(6), 778-782 (1993). (Pubitemid 23185103)
45. Hirakawa H, Fukuda Y, Tanida N et al. Home elemental enteral hyperalimentation (HEEH) for the maintenance of remission in patients with Crohn's disease. Gastroenterol. Jpn 28(3), 379-384 (1993). (Pubitemid 23208894)
46. Rigaud D, Cosnes J, Le Quintrec Y et al. Controlled trial comparing two types of enteral nutrition in treatment of active Crohn's disease: elemental versus polymeric diet. Gut 32(12), 1492-1497 (1991).
47. Demetriou AA. Comparison of enteral nutrition and drug treatment in active Crohn's disease: results of the European Cooperative Crohn's Disease Study IV. JPEN J. Parenter. Enteral. Nutr. 16(1), 84-85 (1992).
48. Abad-Lacruz A, González-Huix F, Esteve M et al. Liver function tests abnormalities in patients with inflammatory bowel disease receiving artificial nutrition: a prospective randomized study of total enteral nutrition vs total parenteral nutrition. JPEN J. Parenter. Enteral. Nutr. 14(6), 618-621 (1990).
49. Giaffer MH, North G, Holdsworth CD. Controlled trial of polymeric versus elemental diet in treatment of active Crohn's disease. Lancet 335(8693), 816-819 (1990). (Pubitemid 20113734)
50. Greenberg GR, Fleming CR, Jeejeebhoy KN et al. Controlled trial of bowel rest and nutritional support in the management of Crohn's disease. Gut 29(10), 1309-1315 (1988).
51. Belli DC, Seidman E, Bouthillier L et al. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology 94(3), 603-610 (1988). (Pubitemid 18073519)
52. Akobeng AI, Clayton PE, Miller V et al. Low serum concentrations of insulin-like growth factor-I in children with active Crohn disease: effect of enteral nutritional support and glutamine supplementation. Scand. J. Gastroenterol. 37(12), 1422-1427 (2002). (Pubitemid 36051503)
53. Akobeng AK, Miller V, Stanton J et al. Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn's disease. J. Pediatr. Gastroenterol. Nutr. 30(1), 78-84 (2000). (Pubitemid 30349950)
54. Schneeweiss B, Lochs H, Zauner C et al. Energy and substrate metabolism in patients with active Crohn's disease. J. Nutr. 129(4), 844-848 (1999). (Pubitemid 29162378)
55. Stolk MF, Van Erpecum KJ, Hiemstra G et al. Gallbladder motility and cholecystokinin release during long-term enteral nutrition in patients with Crohn's disease. Scand. J. Gastroenterol. 29(10), 934-939 (1994). (Pubitemid 24315925)
56. Lochs H, Steinhardt HJ, Klaus-Wentz B, Zeitz M et al. Comparison of enteral nutrition and drug treatment in active Crohn's disease. Results of the European Cooperative Crohn's Disease Study. IV. Gastroenterology 101(4), 881-888 (1991).
57. Matsui T, Sakurai T, Yao T. Nutritional therapy for Crohn's disease in Japan. J. Gastroenterol. 40(Suppl. 16), 25-31 (2005).
58. Axelsson C, Jarnum S. Assessment of the therapeutic value of an elemental diet in chronic inflammatory bowel disease. Scand. J. Gastroenterol. 12(1), 89-95 (1977). (Pubitemid 8031770)
59. Göschke H, Buess H, Gyr K et al. [Elementary diet as an alternative to parenteral feeding in severe gastrointestinal diseases.] Schweiz. Med. Wochenschr. 107(2), 43-49 (1977). (Pubitemid 8014851)
60. O'Morain C. Elemental diets in the treatment of Crohn's disease. Proc. Nutr. Soc. 38, 403 (1979).
61. Yamamoto T, Nakahigashi M, Saniabadi AR et al. Impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal cytokines during remission in patients with Crohn's disease: a prospective study. Inflamm. Bowel Dis. 13(12), 1493-1501 (2007). (Pubitemid 44902865)
62. Rowe AH, Rowe A Jr, Uyeyama K. Regional enteritis; its allergic aspects. Gastroenterology 23(4), 554-571 (1953).
63. Vaisman N, Dotan I, Halack A, Niv E. Malabsorption is a major contributor to underweight in Crohn's disease patients in remission. Nutrition 22(9), 855-859 (2006). (Pubitemid 44234012)
64. Chapman-Kiddell CA, Davies PS, Gillen L, Radford-Smith GL. Role of diet in the development of inflammatory bowel disease. Inflamm. Bowel Dis. 16(1), 137-151 (2010).
65. Hartman C, Eliakim R, Shamir R. Nutritional status and nutritional therapy in inflammatory bowel diseases. World J. Gastroenterol. 15(21), 2570-2578 (2009).
66. Razack R, Seidner DL. Nutrition in inflammatory bowel disease. Curr. Opin. Gastroenterol. 23(4), 400-405 (2007). (Pubitemid 46878952)
67. Rigaud D, Cerf M, Angel Alberto L, Sobhani I, Carduner MJ, Mignon M. [Increase of resting energy expenditure during flare-ups in Crohn disease.] Gastroenterol. Clin. Biol. 17(12), 932-937 (1993). (Pubitemid 24049208)
68. Heyman MB, Garnett EA, Wojcicki J et al. Growth hormone treatment for growth failure in pediatric patients with Crohn's disease. J. Pediatr. 153(5), 651-658, (2008).
69. Finn R. Food allergy - fact or fiction: a review. J. R. Soc. Med. 85(9), 560-564 (1992).
70. Lack G. Clinical practice. Food allergy. N. Engl. J. Med. 359(12), 1252-1260 (2008).
71. Jones VA, Dickinson RJ, Workman E, Wilson AJ, Freeman AH, Hunter JO. Crohn's disease: maintenance of remission by diet. Lancet 2(8448), 177-180 (1985). (Pubitemid 15045074)
72. Giaffer MH, Cann P, Holdsworth CD. Long-term effects of elemental and exclusion diets for Crohn's disease. Aliment. Pharmacol. Ther. 5(2), 115-125 (1991).
73. Pearson M, Teahon K, Levi AJ, Bjarnason I. Food intolerance and Crohn's disease. Gut 34(6), 783-787 (1993). (Pubitemid 23185104)
74. Workman EM, Alun Jones V, Wilson AJ et al. Diet in the management of Crohn's disease. Hum. Nutr. Appl. Nutr. 38(6), 469-473 (1984).
75. Ballegaard M, Bjergstrøm A, Brøndum S et al. Self-reported food intolerance in chronic inflammatory bowel disease. Scand. J. Gastroenterol. 32(6), 569-571 (1997). (Pubitemid 27314267)
76. Joneja JV. Dealing with Food Allergies. Bull Publishing Company, CO, USA (2003).
77. Bischoff SC, Mayer JH, Manns MP. Allergy and the gut. Int. Arch. Allergy Immunol. 121(4), 270-283 (2000).
78. Jones VA. Comparison of total parenteral nutrition and elemental diet in induction of remission of Crohn's disease. Long-term maintenance of remission by personalized food exclusion diets. Dig. Dis. Sci. 32(12 Suppl.), S100-S107 (1987).
79. Stange EF, Schmid U, Fleig WE, Ditschuneit H. Exclusion diet in Crohn disease: a controlled, randomized study. Z. Gastroenterol. 28(10), 561-564 (1990). (Pubitemid 20339874)
80. Riordan AM, Rucker JT, Kirby GA, Hunter JO. Food intolerance and Crohn's disease. Gut 35(4), 571-572 (1994).
81. Thomas AG, Taylor F, Miller V. Dietary intake and nutritional treatment in childhood Crohn's disease. J. Pediatr. Gastroenterol. Nutr. 17(1), 75-81 (1993). (Pubitemid 23199293)
82. Ferguson MM, MacFadyen EE. Orofacial granulomatosis - a 10 year review. Ann. Acad. Med. Singapore 15(3), 370-377 (1986).
83. Kajosaari M. Food allergy in Finnish children aged 1 to 6 years. Acta Paediatr. Scand. 71(5), 815-819 (1982). (Pubitemid 12049539)
84. Walker WA. Allergen absorption in the intestine: implication for food allergy in infants. J. Allergy Clin. Immunol. 78, 1003-1009 (1986).
85. Green TJ, Issenman RM, Jacobson K. Patients' diets and preferences in a pediatric population with inflammatory bowel disease. Can. J. Gastroenterol. 12(8), 544-549 (1998). (Pubitemid 29048046)
86. Simpson JW. Diet and large intestinal disease in dogs and cats. J. Nutr. 128(12 Suppl.), S2717-S2722 (1998).
87. Guilford WG. Nutritional management of gastrointestinal tract diseases of dogs and cats. J. Nutr. 124(12 Suppl.), S2663-S2669 (1994).
88. Forbes A. Review article: Crohn's disease - the role of nutritional therapy. Aliment. Pharmacol. Ther. 16(Suppl. 4), 48-52 (2002). (Pubitemid 34595618)
89. Tanaka M, Iwao Y, Okamoto S, Ogata H, Hibi T, Kazuma K. Coping strategy when patients with quiescent Crohn's disease recognize that their conditions are worsening. J. Gastroenterol. 44(11), 1109-1112 (2009).
90. Niewinski MM. Advances in celiac disease and gluten-free diet. J. Am. Diet. Assoc. 108(4), 661-672 (2008). (Pubitemid 351423383)
91. Joachim G. Responses of people with inflammatory bowel disease to foods consumed. Gastroenterol. Nurs. 23(4), 160-167 (2000).
92. Mantzaris GJ, Roussos A, Koilakou S et al. Prevalence of celiac disease in patients with Crohn's disease. Inflamm. Bowel Dis. 11(11), 1029 (2005). (Pubitemid 41580021)
93. Tursi A, Giorgetti GM, Brandimarte G, Elisei W. High prevalence of celiac disease among patients affected by Crohn's disease. Inflamm. Bowel Dis. 11(7), 662-666 (2005). (Pubitemid 40961080)
94. Leeds JS, Höroldt BS, Sidhu R et al. Is there an association between coeliac disease and inflammatory bowel diseases? A study of relative prevalence in comparison with population controls. Scand. J. Gastroenterol. 42(10), 1214-1220 (2007). (Pubitemid 47537092)
95. A case of Crohn's disease in a patient with treated adult coeliac disease; demonstrated at the Royal Postgraduate Medical School. Br. Med. J. 4(5573), 222-226 (1967).
96. Euler AR, Ament ME. Celiac sprue and Crohn's disease: an association causing severe growth retardation. Gastroenterology 72, 729-731 (1977).
97. Gillberg R, Dotevall G, Ahrén C. Chronic inflammatory bowel disease in patients with coeliac disease. Scand. J. Gastroenterol. 17(4), 491-496 (1982). (Pubitemid 12054331)
98. Bulger K, Griffin M, Dervan P, Lennon J, Crowe J. Coeliac disease in association with inflammatory bowel disease. Postgrad. Med. J. 64(750), 336 (1988).
99. Curtis WD, Schuman BM, Griffin JW Jr. Association of gluten-sensitive enteropathy and Crohn's colitis. Am. J. Gastroenterol. 87(11), 1634-1637 (1992).
100. Karoui S, Boubaker J, Hamzaoui S, Be Yaghlene L, Filali A. [Association of asymptomatic celiac disease and Crohn's disease.] Ann. Med. Interne (Paris) 151(5), 411-412 (2000).
101. Chakraborty A, Bremner AR, Moore I, Beattie RM. Coeliac disease and Crohn's disease: an association not to be forgotten. Hosp. Med. 64(11), 684-685 (2003). (Pubitemid 38918415)
102. Schedel J, Rockmann F, Bongartz T, Woenckhaus M, Scholmerich J, Kullmann F. Association of Crohn's disease and latent celiac disease: a case report and review of the literature. Int. J. Colorectal. Dis. 20(4), 376-380 (2005). (Pubitemid 40909238)
103. Anderson CR, Cerda JJ. Dietary therapy in gastrointestinal disease. Compr. Ther. 15(2), 62-65 (1989).
104. Barta Z, Csípö I, Antal-Szalmás P, Sipka S, Szabo G, Szegedi G. [Anti-Saccharomyces cerevisiae antibodies in patients with Crohn's disease.] Orv. Hetil. 142(42), 2303-2307 (2001).
105. Vernia P, Di Camillo M, Marinaro V. Lactose malabsorption, irritable bowel syndrome and self-reported milk intolerance. Dig. Liver Dis. 33(3), 234-239 (2001). (Pubitemid 32452056)
106. Ehrenpreis ED. Irritable bowel syndrome. 10% to 20% of older adults have symptoms consistent with diagnosis. Geriatrics 60(1), 25-28 (2005).
107. McBean LD, Miller GD. Allaying fears and fallacies about lactose intolerance. J. Am. Diet. Assoc. 98(6), 671-676 (1998).
108. Meryn S. Role of nutrition in acute and long-term therapy of chronic inflammatory bowel diseases. Wien. Klin. Wochenschr. 98(22), 774-779 (1986).
109. Bujanover Y, Katz A, Peled Y, Gilat T. Lactose malabsorption in Israeli children. Isr. J. Med. Sci. 21(1), 32-35 (1985). (Pubitemid 15055825)
110. von Tirpitz C, Kohn C, Steinkamp M et al. Lactose intolerance in active Crohn's disease: clinical value of duodenal lactase analysis. J. Clin. Gastroenterol. 34(1), 49-53 (2002). (Pubitemid 34038479)
111. Barrett JS, Irving PM, Shepherd SJ, Muir JG, Gibson PR. Comparison of the prevalence of fructose and lactose malabsorption across chronic intestinal disorders. Aliment. Pharmacol. Ther. 30(2), 165-174 (2009).
112. Lerner A, Rossi TM, Park B, Albini B, Lebenthal E. Serum antibodies to cow's milk proteins in pediatric inflammatory bowel disease. Crohn's disease versus ulcerative colitis. Acta Paediatr. Scand. 78(3), 384-389 (1989). (Pubitemid 19133187)
113. Jewell DP, Truelove SC. Circulating antibodies to cow's milk proteins in ulcerative colitis. Gut 13(10), 796-801 (1972).
114. Gudmand-Høyer E. The clinical significance of disaccharide maldigestion. Am. J. Clin. Nutr. 59(3 Suppl.), S735-S741 (1994). (Pubitemid 24093513)
115. Ojetti V, Nucera G, Migneco A et al. High prevalence of celiac disease in patients with lactose intolerance. Digestion 71(2), 106-110 (2005). (Pubitemid 40674578)
116. Harrer M, Reinisch W, Dejaco C et al. Do high serum levels of anti-Saccharomyces cerevisiae antibodies result from a leakiness of the gut barrier in Crohn's disease? Eur. J. Gastroenterol. Hepatol. 15(12), 1281-1285 (2003). (Pubitemid 39049670)
117. Hollander D. Permeability in Crohn's disease: altered barrier functions in healthy relatives? Gastroenterology 104(6), 1848- 1851 (1993). (Pubitemid 23235481)
118. Peeters M, Geypens B, Claus D et al. Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology 113(3), 802-807 (1997). (Pubitemid 27381139)
119. Mishkin B, Yalovsky M, Mishkin S. Increased prevalence of lactose malabsorption in Crohn's disease patients at low risk for lactose malabsorption based on ethnic origin. Am. J. Gastroenterol. 92(7), 1148-1153 (1997). (Pubitemid 27304811)
120. Banos G, Brotherstone S, Coffey MP. Evaluation of body condition score measured throughout lactation as an indicator of fertility in dairy cattle. J. Dairy Sci. 87(8), 2669-2676 (2004). (Pubitemid 39103995)
121. Gudmand-Hoyer E, Jarnum S. Incidence and clinical significance of lactose malabsorption in ulcerative colitis and Crohn's disease. Gut 11(4), 338-343 (1970).
122. Hass SV, Hass MP. Management of Celiac Disease. Lippincott, PA, USA (1951).
123. Heaton KW, Thornton JR, Emmett PM. Treatment of Crohn's disease with an unrefined-carbohydrate, fibre-rich diet. Br. Med. J. 2(6193), 764-766 (1979). (Pubitemid 10231335)
124. Ritchie JK, Wadsworth J, Lennard-Jones JE, Rogers E. Controlled multicentre therapeutic trial of an unrefined carbohydrate, fibre rich diet in Crohn's disease. Br. Med. J. (Clin. Res. Ed.) 295(6597), 517-520 (1987). (Pubitemid 17120997)
125. Brandes JW, Lorenz-Meyer H. Sugar free diet: a new perspective in the treatment of Crohn disease? Randomized, control study. Z. Gastroenterol. 19(1), 1-12 (1981). (Pubitemid 11171415)
126. Lorenz-Meyer H, Bauer P, Nicolay C et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group). Scand. J. Gastroenterol. 31(8), 778-785 (1996).
127. Nieves R, Jackson RT. Specific carbohydrate diet in treatment of inflammatory bowel disease. Tenn. Med. 97(9), 407 (2004).
128. Arnott ID, Landers CJ, Nimmo EJ et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am. J. Gastroenterol. 99(12), 2376-2384 (2004). (Pubitemid 40039369)
129. Ashorn S, Honkanen T, Kolho KL et al. Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease. Inflamm. Bowel Dis. 15(2), 199-205 (2009).
130. Aydin SZ, Atagunduz P, Temel M, Bicakcigil M, Tasan D, Direskeneli H. Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthropathies: a reassessment. Rheumatology (Oxford) 47(2), 142-144 (2008). (Pubitemid 351168221)
131. Barclay GR, McKenzie H, Pennington J et al. The effect of dietary yeast on the activity of stable chronic Crohn's disease. Scand. J. Gastroenterol. 27(3), 196-200 (1992).
132. Desplat-Jégo S, Johanet C, Escande A et al. Update on anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study. World J. Gastroenterol. 13(16), 2312-2318 (2007). (Pubitemid 46860731)
133. Fresko I, Ugurlu S, Ozbakir F et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Behçet's syndrome. Clin. Exp. Rheumatol. 23(4 Suppl. 38), S67-S70 (2005).
134. Kim BC, Park S, Han J et al. Clinical significance of anti-Saccharomyces cerevisiae antibody (ASCA) in Korean patients with Crohn's disease and its relationship to the disease clinical course. Dig. Liver Dis. 39(7), 610-616 (2007). (Pubitemid 46888207)
135. Lindberg E, Magnusson KE, Tysk C, Janerot G. Antibody (IgG, IgA, and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease. Gut 33(7), 909-913 (1992).
136. Mallant-Hent RCh, Mary B, von Blomberg E et al. Disappearance of anti-Saccharomyces cerevisiae antibodies in coeliac disease during a gluten-free diet. Eur. J. Gastroenterol. Hepatol. 18(1), 75-78 (2006). (Pubitemid 43004885)
137. Makharia GK, Sachdev V, Gupta R, Lal S, Pandey RM. Anti-Saccharomyces cerevisiae antibody does not differentiate between Crohn's disease and intestinal tuberculosis. Dig. Dis. Sci. 52(1), 33-39 (2007). (Pubitemid 46122044)
138. Riis L, Vind I, Vermeire S et al.; European Collaborative Study Group on Inflammatory Bowel Disease. The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients. Inflamm. Bowel Dis. 13(1), 24-32 (2007). (Pubitemid 46080006)
139. Sutton CL, Yang H, Li Z, Rotter JI, Targen SR, Braun J. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease. Gut 46(1), 58-63 (2000). (Pubitemid 30307678)
140. Suzuki H, Fukuda Y, Koizuka H et al. Dietary antigens in Crohn's disease: antibodies to porcine pancreatic amylase. Am. J. Gastroenterol. 103(3), 656-664 (2008). (Pubitemid 351405989)
141. Oshitani N, Hato F, Matsumoto T et al. Decreased anti-Saccharomyces cerevisiae antibody titer by mesalazine in patients with Crohn's disease. J. Gastroenterol. Hepatol. 15(12), 1400-1403 (2000). (Pubitemid 32052913)
142. Barahona-Garrido J, Sarti HM, Barahona-Garrido MK et al. Serological markers in inflammatory bowel disease: a review of their clinical utility. Rev. Gastroenterol. Mex. 74(3), 230-237 (2009).
143. Lichtenstein GR, Olson A, Travers S et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am. J. Gastroenterol. 101(5), 1030-1038 (2006). (Pubitemid 43725317)
144. Forcione DG, Rosen MJ, Kisiel JB, Sands BE. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut 53(8), 1117-1122 (2004).
145. Van Den Bogaerde J, Cahill J, Emmanuel AV et al. Gut mucosal response to food antigens in Crohn's disease. Aliment. Pharmacol. Ther. 16(11), 1903-1915 (2002). (Pubitemid 35253006)
146. Tragnone A, Valpiani D, Miglio F et al. Dietary habits as risk factors for inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 7(1), 47-51 (1995).
147. Shoda R, Matsueda K, Yamato S, Umeda N. Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am. J. Clin. Nutr. 63(5), 741-745 (1996). (Pubitemid 26126594)
148. Reif S, Klein I, Lubin F, Farbstein M, Hallak A, Gilat T. Pre-illness dietary factors in inflammatory bowel disease. Gut 40(6), 754-760 (1997). (Pubitemid 27305468)
149. Nieuwenhuizen WF, Pieters RH, Knippels LM, Jansen MC, Koppelman SJ. Is Candida albicans a trigger in the onset of coeliac disease? Lancet 361(9375), 2152-2154 (2003). (Pubitemid 36782265)
150. Mpofu CM, Campbell BJ, Subramanian S et al. Microbial mannan inhibits bacterial killing by macrophages: a possible pathogenic mechanism for Crohn's disease. Gastroenterology 133(5), 1487-1498 (2007). (Pubitemid 350029735)
151. Jawhara S, Thuru X, Standaert-Vitse A et al. Colonization of mice by Candida albicans is promoted by chemically induced colitis and augments inflammatory responses through galectin-3. J. Infect. Dis. 197(7), 972-980 (2008). (Pubitemid 351590025)
152. Benjamin J, Makharia GK, Joshi YK. Association between intestinal permeability and anti-Saccharomyces cerevisiae antibodies in patients with Crohn's disease. Inflamm. Bowel Dis. 14(11), 1610-1611 (2008).
153. Cummings JH, Antoine JM, Azpiroz F et al. PASSCLAIM - gut health and immunity. Eur J Nutr. 43(Suppl. 2), II118-II173 (2004).
154. Fasano A. Surprises from celiac disease. Sci. Am. 301(2), 54-61 (2009).
155. Lomer MC, Harvey RS, Evans SM, Thompson RP, Powell JJ. Efficacy and tolerability of a low microparticle diet in a double blind, randomized, pilot study in Crohn's disease. Eur. J. Gastroenterol. Hepatol. 13(2), 101-106 (2001).
156. Lomer MC, Grainger SL, Ede R et al. Lack of efficacy of a reduced microparticle diet in a multi-centred trial of patients with active Crohn's disease. Eur. J. Gastroenterol. Hepatol. 17(3), 377-384 (2005). (Pubitemid 40411227)
157. Bartel G, Weiss I, Turetschek K, Schima W et al. Ingested matter affects intestinal lesions in Crohn's disease. Inflamm. Bowel Dis. 14(3), 374-382 (2008). (Pubitemid 351441327)
158. Sullivan SN. Hypothesis revisited: toothpaste and the cause of Crohn's disease. Lancet 336(8723), 1096-1097 (1990).
159. Chess S, Olander G, Puestow CB, Benner W, Chess D. Regional enteritis; clinical and experimental observations. Surg. Gynecol. Obstet. 91(3), 343-350 (1950).
160. Coffey RJ. Pathologic manifestations of regional enteritis. Mayo Clin.
161. Shepherd NA, Crocker PR, Smith AP, Levison DA. Exogenous pigment in Peyer's patches. Hum. Pathol. 18(1), 50-54 (1987).
162. Powell JJ, Ainley CC, Harvey RS. Characterisation of inorganic microparticles in pigment cells of human gut associated lymphoid tissue. Gut 38(3), 390-395 (1996).
163. Powell JJ, Harvey RS, Ashwood P et al. Immune potentiation of ultrafine dietary particles in normal subjects and patients with inflammatory bowel disease. J. Autoimmun. 14(1), 99-105 (2000). (Pubitemid 30080542)
164. Mahmud N, Weir DG. The urban diet and Crohn's disease: is there a relationship? Eur. J. Gastroenterol. Hepatol. 13(2), 93-95 (2001). (Pubitemid 32158199)
165. Van Gossum M, Mascart F, Rickaert F, Codden T, Colonius V. [Lactose and gluten intolerance: which to suscept?] Rev. Med. Brux. 21(4), A303-A308 (2000).